Logo image of IBO

IMPACT BIOMEDICAL INC (IBO) Stock Fundamental Analysis

NYSEARCA:IBO - NYSE Arca - US45259L2051 - Common Stock - Currency: USD

0.55  -0.02 (-4.35%)

Premarket: 0.544 -0.01 (-1.09%)

Fundamental Rating

0

IBO gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of IBO have multiple concerns. IBO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IBO had negative earnings in the past year.
In the past year IBO has reported a negative cash flow from operations.
IBO Yearly Net Income VS EBIT VS OCF VS FCFIBO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

IBO's Return On Assets of -121.79% is on the low side compared to the rest of the industry. IBO is outperformed by 78.28% of its industry peers.
IBO's Return On Equity of -580.23% is on the low side compared to the rest of the industry. IBO is outperformed by 78.28% of its industry peers.
Industry RankSector Rank
ROA -121.79%
ROE -580.23%
ROIC N/A
ROA(3y)-48.88%
ROA(5y)N/A
ROE(3y)-207.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBO Yearly ROA, ROE, ROICIBO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IBO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBO Yearly Profit, Operating, Gross MarginsIBO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -5K -10K

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for IBO remains at a similar level compared to 1 year ago.
IBO has a worse debt/assets ratio than last year.
IBO Yearly Shares OutstandingIBO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M 8M 10M
IBO Yearly Total Debt VS Total AssetsIBO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -3.34, we must say that IBO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.34, IBO perfoms like the industry average, outperforming 44.44% of the companies in the same industry.
A Debt/Equity ratio of 2.08 is on the high side and indicates that IBO has dependencies on debt financing.
IBO has a Debt to Equity ratio of 2.08. This is in the lower half of the industry: IBO underperforms 76.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.08
Debt/FCF N/A
Altman-Z -3.34
ROIC/WACCN/A
WACCN/A
IBO Yearly LT Debt VS Equity VS FCFIBO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

IBO has a Current Ratio of 0.25. This is a bad value and indicates that IBO is not financially healthy enough and could expect problems in meeting its short term obligations.
IBO's Current ratio of 0.25 is on the low side compared to the rest of the industry. IBO is outperformed by 93.43% of its industry peers.
IBO has a Quick Ratio of 0.25. This is a bad value and indicates that IBO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of IBO (0.25) is worse than 92.42% of its industry peers.
Industry RankSector Rank
Current Ratio 0.25
Quick Ratio 0.25
IBO Yearly Current Assets VS Current LiabilitesIBO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

IBO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -509.26%.
EPS 1Y (TTM)-509.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2093.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IBO Yearly Revenue VS EstimatesIBO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 10K 20K 30K 40K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IBO. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBO Price Earnings VS Forward Price EarningsIBO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBO Per share dataIBO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

IBO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMPACT BIOMEDICAL INC

NYSEARCA:IBO (5/22/2025, 8:12:15 PM)

Premarket: 0.544 -0.01 (-1.09%)

0.55

-0.02 (-4.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.89%
Inst Owner Change563.24%
Ins Owners40.56%
Ins Owner Change-384.98%
Market Cap6.65M
AnalystsN/A
Price TargetN/A
Short Float %3.86%
Short Ratio0.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.46
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0
BVpS0.35
TBVpS-1.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -121.79%
ROE -580.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.88%
ROA(5y)N/A
ROE(3y)-207.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.25
Quick Ratio 0.25
Altman-Z -3.34
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-509.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2093.02%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-36.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.46%
OCF growth 3YN/A
OCF growth 5YN/A